{"brief_title": "A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either \"Responders\" or \"Non-Responders\" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.", "brief_summary": "The primary objective of this study is to determine the relapse rate in patients with AIDS-related diarrhea who were found to be \"Responders\" in a previous placebo-controlled, double-blind study of Sandostatin (Study #D203 - FDA 102A). The secondary objectives include: 1) To evaluate clinical efficacy and safety of open-label Sandostatin in patients who were \"Non-Responders\" in Study #D203 - FDA 102A; 2) To evaluate the efficacy and safety of Sandostatin during prolonged open-label treatment in \"Responders\" from Study #D03 - FDA 102A.", "condition": ["Diarrhea", "HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Octreotide"], "criteria": "Inclusion Criteria Patients must have the following: - Only patients who have completed the duration of Study D203, FDA 102A will be eligible for this study. - Each of these patients must give written informed consent to participate in Study D204, FDA 102B as well.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "AIDS-Related Complex", "mesh_term": ["HIV Infections", "Diarrhea", "Immunologic Deficiency Syndromes", "Octreotide"], "id": "NCT00002253"}